Update on Antifungal Therapy for Systemic Infections

update on zika virus infections

Antifungal therapy in invasive fungal infections.

Early treatment of invasive fungal infections (IFIs) is essential for optimal clinical outcomes. Standard antifungal drugs (polyenes, azoles and echinocandins) are not predictably effective against emerging yeasts and filamentous fungi and may cause undesirable side effects. Species identification can guide antifungal selection for invasive candidiasis, but not less common moulds such as Scedos...

Update on herpesvirus infections.

The eight human herpesviruses (HHV) have features in common, yet are also distinct (see Tables 1 and 2). Each herpesvirus causes more than one disease by interacting in multiple ways with the host. They have also evolved multiple ways of impairing cellmediated immune responses by downregulating display of HLA molecules on the surface of infected cells. The herpesviruses are divided into three s...

B-cell-targeted therapy for systemic lupus erythematosus: an update.

Systemic lupus erythematosus (SLE) is a classic autoimmune disease characterized by a myriad of immune system aberrations, most likely resulting from pathogenic autoantibody production, immune complex deposition, and subsequent end-organ damage. B cells play a key role in the pathogenesis; therefore, B-cell-targeted therapies, including B-cell depletion and blockage of B-cell survival factors s...

The impact of periodontal infections on systemic diseases. An update for medical practitioners.

Oral health status is an integral component of a general health and well-being of an individual. Knowledge about the link between periodontal disease and systemic diseases are growing rapidly. Increasing evidence is available from many investigators to indicate periodontitis as a risk factor for cardiovascular diseases, diabetes mellitus, low birth weight infants and pulmonary diseases. Both ep...